Skip to main content

Table 6 Fisher’s exact test for AFF in univariate analysis

From: Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

 

Category

Incidence rate (95% CI)

p-value

All

 

0.018 (0.006–0.042)

 

Primary disease

Breast

0.025 (0.007–0.064)

0.3968

Other

0.008 (0–0.046)

 

Stage at diagnosis

Stage 1–2

0.013 (0–0.069)

1

Stage 3–4

0.014 (0.002–0.051)

 

Gender

Female

0.027 (0.009–0.063)

0.1713

Male

0 (0–0.039)

 

Age

< 65

0.023 (0.005–0.065)

0.6716

> = 65

0.014 (0.002–0.049)

 

Metastatic site: liver

No

0.03 (0.01–0.068)

0.1601

Yes

0 (0–0.034)

 

Metastatic site: lung

No

0.013 (0.002–0.045)

0.6548

Yes

0.025 (0.005–0.072)

 

Metastatic site: lymph node

No

0.023 (0.005–0.066)

0.669

Yes

0.014 (0.002–0.049)

 

Metastatic site: femur

No

0.021 (0.007–0.049)

1

Yes

0 (0–0.086)

 

Number of denosumab doses

< 10

0 (0–0.027)

0.0605

> = 10

0.035 (0.012–0.081)

 

Number of denosumab doses

< 25

0.005 (0–0.025)

0.0057

> = 25

0.074 (0.021–0.179)

 

Prior zoledronic acid treatment

No

0.006 (0–0.033)

0.0151

Yes

0.071 (0.02–0.173)

Â